



Tezepelumab-ekko in India

The CDSCO named-patient coordination pathway — indicative 2026

IMMUNOLOGY · SEVERE UNCONTROLLED ASTHMA

The clinical situation

Tezepelumab-ekko (US brand Tezspire) is a subcutaneous anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody FDA-approved as add-on maintenance therapy for severe uncontrolled asthma, independent of eosinophil or IgE phenotype. Manufactured by Amgen and AstraZeneca. Dosing is 210 mg SC every 4 weeks. Pre-treatment workup confirms severe asthma despite high-dose ICS-LABA, documents exacerbation pattern, and ensures vaccination currency per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your pulmonologist or allergist documents severe-asthma history, prior biologics, exacerbation pattern, and Tezepelumab-ekko rationale (phenotype-independent use).
- 2 Baseline screening.** Parasitic infection screen where indicated, vaccinations, and spirometry baseline per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; first dose administered in-office with subsequent doses per protocol.

Indicative economics

Reference US cash-pay range: USD 3,800–4,400 per month of Tezepelumab-ekko (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Amgen/AstraZeneca authorised distribution.

Documentation. Physician kit tailored to CDSCO review, with severe-asthma biologic class annex. **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through each monthly cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Tezepelumab-ekko × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/tezepelumab-ekko-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team